PomDoctor Ltd · Q3 2025 earnings

Briefing

Pomdoctor H1 revenue up 16% to RMB174M as internet-hospital sales surge 82%

Pomdoctor Limited reported unaudited results for the six months ended June 30, 2025. Net revenues rose 16.2% to RMB174.5 million from RMB150.2 million a year earlier, driven by an 82.4% increase in internet hospital revenue to RMB67.2 million, including online pharmacy sales up to RMB66.4 million. Gross profit increased 16.3% to RMB28.3 million while gross margin held steady at 16.2%. The company posted a net loss of RMB19.9 million versus RMB14.0 million in the prior-year half, with a basic and diluted loss per share of RMB11.45. Operating loss widened to RMB13.5 million from RMB8.9 million amid higher sales and marketing and IPO-related general and administrative expenses.

• Net revenues of RMB174.5M (+16.2% YoY) with internet hospital revenue up 82.4% to RMB67.2M.
• Online pharmacy sales within internet hospital grew from RMB36.3M to RMB66.4M on expanded pharma manufacturer partnerships.
• Gross profit rose 16.3% to RMB28.3M with stable 16.2% gross margin despite mix shift to lower-margin pharmacy products.
• Net loss widened to RMB19.9M (RMB11.45 per share) from RMB14.0M on higher doctor service fees and IPO costs.
• Company completed its Nasdaq IPO in October 2025, raising gross proceeds of US$23.0M before fees.

Headline financials

Revenue & EPS history